Drug Trial Radar · NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Aug 5, 2024
Primary completion
Feb 10, 2027
Study completion Feb 10, 2027
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions
- Carcinoma, Hepatocellular
Interventions
HLX53 (1000mg)Drug
HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
HLX53 (2000mg)Drug
HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
HLX10Drug
HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
HLX04Drug
HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
PlaceboOther
Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 24 weeks
- PFSTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 14 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.